BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30237581)

  • 1. Genetic markers in methotrexate treatments.
    Giletti A; Esperon P
    Pharmacogenomics J; 2018 Dec; 18(6):689-703. PubMed ID: 30237581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
    Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
    Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
    Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
    Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.
    Giletti A; Vital M; Lorenzo M; Cardozo P; Borelli G; Gabus R; Martínez L; Díaz L; Assar R; Rodriguez MN; Esperón P
    Eur J Pharm Sci; 2017 Nov; 109():480-485. PubMed ID: 28887233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
    Kumagai K; Hiyama K; Oyama T; Maeda H; Kohno N
    Int J Mol Med; 2003 May; 11(5):593-600. PubMed ID: 12684695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetics of high-dose methotrexate-induced oral mucositis: current perspectives.
    Heil SG
    Pharmacogenomics; 2019 Jun; 20(9):621-623. PubMed ID: 31250729
    [No Abstract]   [Full Text] [Related]  

  • 7. Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.
    Yousef AM; Farhad R; Alshamaseen D; Alsheikh A; Zawiah M; Kadi T
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):755-762. PubMed ID: 30684021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
    Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
    Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate.
    Galbiatti AL; Castro R; Caldas HC; Padovani JA; Pavarino EC; Goloni-Bertollo EM
    Tumour Biol; 2013 Dec; 34(6):3765-71. PubMed ID: 23838799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics of Methotrexate: Current Status and Future Outlook.
    Cao M; Guo M; Wu DQ; Meng L
    Curr Drug Metab; 2018; 19(14):1182-1187. PubMed ID: 29283070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.
    Erčulj N; Kotnik BF; Debeljak M; Jazbec J; Dolžan V
    Leuk Lymphoma; 2012 Jun; 53(6):1096-104. PubMed ID: 22074251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
    Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
    Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
    Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
    Campbell JM; Bateman E; Stephenson MD; Bowen JM; Keefe DM; Peters MD
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):27-39. PubMed ID: 27142726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms predicting methotrexate blood levels and toxicity in adult non-Hodgkin lymphoma.
    Avivi I; Zuckerman T; Krivoy N; Efrati E
    Leuk Lymphoma; 2014 Mar; 55(3):565-70. PubMed ID: 23829278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.
    Jenko B; Lusa L; Tomsic M; Praprotnik S; Dolzan V
    Pharmacogenomics J; 2017 Oct; 17(5):412-418. PubMed ID: 27217051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia.
    Al-Sheikh A; Yousef AM; Alshamaseen D; Farhad R
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):379-385. PubMed ID: 33170323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients.
    Lambrecht L; Sleurs C; Labarque V; Dhooge C; Laenen A; Sinnaeve F; Renard M; Uyttebroeck A
    Pharmacogenomics; 2017 Jun; 18(8):787-795. PubMed ID: 28592186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of methotrexate in pediatric hematological neoplasm treatment: does it need a personalized regimen based on MTHFR polymorphisms?
    D'Angelo V; Ramaglia M; Iannotta A; Addeo R
    Expert Rev Hematol; 2014 Oct; 7(5):517-9. PubMed ID: 25213457
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry.
    Salazar J; Garcia-Planella E; Fernández-Clotet A; Esteve M; Gisbert JP; Busquets D; Lucendo A; Márquez L; Guardiola J; Martín-Arranz MD; Iglesias E; Monfort D; Villoria A; Cañete F; Bell O; Ricart E; Zabana Y; Chaparro M; Domènech E; Gordillo J;
    Br J Clin Pharmacol; 2024 May; 90(5):1301-1311. PubMed ID: 38369687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.